Status:
COMPLETED
Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
United States Department of Defense
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to find a way to learn the hormone receptor status of a tumor before surgery is done. By testing for the hormone receptor proteins, doctors can find out if the breast canc...
Eligibility Criteria
Inclusion
- Male and Female patients
- Aged 18 or older at the time of breast cancer diagnosis
- Patients with invasive breast cancer at least 1 cm in size. Patients who have had a prior surgical excision are eligible provided there is a residual of at least a 1 cm area suspected on imaging studies.
- Histopathologic review at MSKCC confirming diagnosis of invasive breast cancer (ductal, lobular, or inflammatory breast cancer).
- Patients who are operative candidates. Patient will have surgery to include either mastectomy or lumpectomy. Radiologic assisted excisions such as needle localization are also eligible.
- Patients with bilateral breast cancer are eligible.
- Patients with metastatic cancer, provided they need surgical biopsy.
- Patients who are undergoing sentinel node mapping (day before or sameday mapping).
- Patient must sign informed consent.
Exclusion
- Previous or concurrent malignancy (except basal and squamous skin cancer and stage 0 cervical cancer)
- Patients who are pregnant or nursing
- Patients unable to tolerate PET or PET/CT
- Patients with known active infection, autoimmune or inflammatory disease such as sarcoidosis, and rheumatoid arthritis.
- Patients with non invasive breast cancer such as DCIS.
- Patients who have received prior radiation therapy to the affected breast.
- Patients who have received prior chemotherapy, including neoadjuvant chemotherapy or hormonal therapy for breast cancer.
- Patients living in a residential care or correctional facility.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00647790
Start Date
November 1 2006
End Date
June 1 2013
Last Update
August 13 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065